All Stories

Bavarian Nordic catches up to rival Valneva with broad ...

Valneva may have won the chikungunya vaccine race with its world-first approval,...

As BMS-paired triplet misses survival mark in kidney ca...

While Exelixis has abandoned a plan to seek an FDA approval for a combination of...

FDA signs off on Sanofi's insulin biosimilar, the first...

The FDA has given a thumbs up to Sanofi’s Merilog as the first biosimilar substi...

Regulatory tracker: Merck's Welireg wins 2 European app...

In this tracker, Fierce Pharma is recording the regulatory progress of in-market...

ICU Medical recalls potassium chloride IV bags over lab...

ICU Medical has voluntarily recalled two lots of potassium chloride intravenous ...

Argenx puts marketing muscle behind CIDP launch with Vy...

Argenx is urging patients to “Live Vyvidly.” The biotech put the message out in ...

Leerink group goes beyond conventional metrics to evalu...

Leerink Partners has launched the Center for Pharmacoeconomics, which is an effo...

UCB's Bimzelx outpacing AbbVie's Rinvoq, Skyrizi on awa...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights find...

With new FDA approval, GSK joins Pfizer in the 5-in-1 m...

The company's Penmenvy combines components of its established MenB and MenACWY v...

FDA approves Ono's rare tumor drug from $2.4B Deciphera...

The new FDA approval gives Daiichi Sankyo’s Turalio some company in a rare tumor...

Inizio Evoke alums flex healthcare marketing prowess wi...

A group of former leaders from health comms giant Inizio Evoke have come togethe...

Moderna shoulders $238M contract manufacturing cancella...

In 2024’s fourth quarter, Moderna’s cost of sales came out to $739 million, whic...

Fierce Pharma Asia—Astellas' investment focus; Mitsubis...

Astellas is shifting its investment focus toward more established modalities and...

UCB’s Bimzelx outpacing AbbVie’s Rinvoq, Skyrizi on awa...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights find...

Regulatory tracker: Europe approves CSL's HAE drug, Arc...

In this tracker, Fierce Pharma is recording the regulatory progress of in-market...

A heartwarming roundup of cardiovascular news and most-...

This week on "The Top Line," we celebrate Valentine's Day with a discussion abou...

Bristol Myers Squibb comes up short in bid to expand Op...

Bristol Myers Squibb is striking out in its attempts to broaden the label of its...

Moderna trims digital team, lays off employees as chief...

Moderna is revamping its digital team, eliminating 10% of roles under two digita...

Alnylam touts Amvuttra's potential move into ATTR-CM as...

As Alnylam approaches its highly anticipated March 23 FDA decision date for a po...

Astellas' eye med Izervay lands key FDA label update, a...

The geographic atrophy drug can now be dosed beyond a 12-month window, a prior l...

It’s official: Senate votes to confirm RFK Jr. as HHS s...

The Senate on Thursday voted 52-48 to confirm President Donald Trump's nominee f...

Rovi warns analyst profit consensus is too high, cites ...

Spanish drugmaker Rovi warned this month that analyst consensus estimates for it...

Pfizer outlines Talzenna's survival benefit in bid for ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to furth...

CDMO Axplora reveals €50M expansion at French productio...

Axplora, a German CDMO that specializes in API small molecule and ADC production...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.